Recent Updates
Recently added Catalysts
CMPX Positive Sentiment Score: 70/100

Compass Therapeutics to Participate in Upcoming September Investor Events

Key Takeaway: Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its upcoming participation in several prominent investor events throughout September 2025. These events include major conferences hosted by Citi, Cantor, H.C. Wainwright, and Morgan Stanley, which will take place in Boston and New York. The company continues to focus on developing antibody-based therapeutics aimed at oncology and other diseases, highlighting its commitment to advancing its innovative pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Compass Therapeutics is actively participating in key investor events.
  • The company is advancing its oncology-focused therapeutic pipeline.
  • Involvement in multiple prestigious healthcare conferences showcases company growth.

Full Press Release Details

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September.
Details are as follows:
Citi’s 2025 Biopharma Back to School Conference
Location: Boston, MA
Date: Tuesday, September 2, 2025
Cantor Global Healthcare Conference
Location: New York, NY
Date: Wednesday, September 3, 2025
H.C. Wainwright 27th Annual Global Investment Conference
Location: New York, NY
Date: Monday, September 8, 2025
Morgan Stanley 23rd Annual Global Healthcare Conference
Location: New York, NY
Date: Tuesday, September 9, 2025
Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Anna Gifford, Chief of Staff

Tags

Frequently Asked Questions

What events will Compass Therapeutics attend in September 2025?

Compass Therapeutics will attend several conferences, including Citi’s 2025 Biopharma Conference, Cantor Global Healthcare Conference, H.C. Wainwright's Annual Investment Conference, and Morgan Stanley's Global Healthcare Conference.

Where is Compass Therapeutics headquartered?

Compass Therapeutics is headquartered in Boston, Massachusetts.

What type of company is Compass Therapeutics?

Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology.

How can I access webcast presentations from Compass?

Webcast presentations will be available for replay on Compass' Events page for 90 days.

Last updated: Aug 26, 2025